All Clinical Services

Preimplantation genetic diagnosis (PGD) is a screening test used to determine if genetic or chromosomal disorders are present in embryos produced through in vitro fertilization (IVF). Preimplantation genetic diagnosis screens embryos before they are transferred to the uterus so couples can make informed decisions about their next steps in the IVF process. Embryos unaffected by the genetic or chromosomal disorder can be selected for transfer to the uterus.

For couples undergoing IVF, preimplantation genetic diagnosis may be recommended when:

Thousands of clinical preimplantation genetic diagnosis cycles have been performed worldwide, resulting in the birth of hundreds of healthy babies.

Preimplantation genetic diagnosis can be used to determine if embryos produced through in vitro fertilization carry a gene mutation associated with a specific genetic disorder, such as cystic fibrosis or muscular dystrophy.

The benefit of preimplantation genetic diagnosis is that the diagnosis can be made before the embryos are transferred to the uterus and a pregnancy is established. Embryos unaffected by the genetic disorder can be selected for transfer to the uterus, therefore greatly reducing the risk that a couple will pass a genetic disorder onto their child.

Couples who are at high risk of having a child with a severe genetic disorder may choose preimplantation genetic diagnosis for many reasons, including:

Preimplantation genetic diagnosis is also offered to couples when one partner has a chromosomal abnormality, such as an unbalanced translocation or anerplocity. If the abnormality is present in the embryo, the condition could ultimately prevent embryo implantation, lead to pregnancy loss, or result in the birth of a child with congenital malformations (physical problems) or mental retardation.

The benefit of preimplantation genetic diagnosis is that the diagnosis can be made before the embryos are transferred to the uterus and a pregnancy is established. Embryos unaffected by the chromosomal abnormality can be selected for transfer to the uterus, therefore greatly reducing the risk that the pregnancy will be adversely affected by the chromosomal abnormality.

Couples who are at high risk of having a child with a chromosomal disorder may choose preimplantation genetic diagnosis for many reasons, including:

Genetic counseling is an important step to determine if preimplantation genetic diagnosis is an appropriate option for a patient. Penn Fertility Care providers work closely with the genetic counselors in Penns Division of Reproductive Genetics. For couples undergoing IVF who are concerned that their child may inherit a genetic disorder or chromosomal abnormality, genetic counselors are available to discuss options and can advise patients on how raising a handicapped child may affect a family.

Learn more about Genetic Counseling services at Penn

Preimplantation genetic diagnosis is available for couples undergoing IVF. The steps of the IVF process include:

Embryo biopsy may be performed after 3 days of culture in the laboratory. The embryos are typically 8-cell embryos on Day-3 and the process involves the removal of one to two cells.

After the biopsy and following receipt of the results from the genetic/chromosomal testing, embryo(s) of the best quality that are not affected by the genetic disorder or chromosomal abnormality) are selected for transfer to the uterus. For day 3 embryo biopsies, the embryo is usually transferred "fresh" following two additional days of culture in the laboratory (Day-5 embryo transfer).

In some cases, the biopsy will be done on either Day-5 or -6 (trophectoderm biopsy). At this stage, the embryo consists of many cells and is called a blastocyst. Cells are removed from the outer layer of cells called the trophectoderm.

Following the biopsy of a good quality blastocyst, the blastocyst is then frozen. When the patient receives the results from the genetic testing, the non-affected or chromosomally normal blastocyst(s) are thawed and transferred in a subsequent frozen embryo cycle.

Embryos are analyzed by one of the techniques described below:

Polymerase Chain Reaction (PCR) is performed on the biopsied cell(s) to determine the presence of a single gene. This is done when a couple has a significantly increased risk of conceiving a child with a severe genetic disorder. When PCR is to be performed, the cell(s) obtained at biopsy is loaded into a tiny tube of medium and sent to for analysis. The specific area of DNA of interest is amplified by making thousands of copies of the DNA through repeated cycles of DNA strand separation and replication. The sample can be analyzed for the presence of a specific sequence of DNA or gene and also for linkage markers near the gene. The biopsied cell(s) are destroyed during this process. Therefore, they cannot be used for another purpose or returned to the embryo.

The genetic material (DNA) within the biopsied cell(s) is amplified using a technique called the polymerase chain reaction (PCR). This amplification produces enough DNA to use a second technique, known as array comparative genomic hybridization (aCGH). Array CGH assesses the amount of DNA derived from each chromosome, revealing whether or not there are both a normal amount and correct number of chromosomes. The biopsied cell(s) are destroyed during this process. Therefore, they cannot be used for another purpose or returned to the embryo. aCGH can be used to screen for numeric abnormalities in all chromosomes and/or known rearrangements of chromosomes (translocations). Array CGH does not detect all types of chromosome aberrations or genetic mutations and cannot distinguish between no translocation present and balanced translocation present.

The results of preimplantation genetic diagnosis are reported to the couple no later than the morning of their scheduled day for embryo transfer. Typically this is five days after oocyte retrieval and in vitro fertilization are performed. Of the embryo(s) that are not affected by the genetic disorder or chromosomal abnormality, the best quality embryo(s) are selected for transfer to the uterus. If additional unaffected and good-quality embryos are available, they may be cryopreserved for a future embryo transfer.

No, preimplantation genetic diagnosis does not replace prenatal testing, such as chorionic villus sampling or amniocentesis. Preimplantation genetic diagnosis provides diagnostic information based on the analysis of asinglecell. Therefore, prenatal testing is still recommended and currently remains the standard of care.

Learn more about prenatal testing services at Penn

For more information about preimplantation genetic diagnosis or to schedule an appointment with a Penn Fertility Care specialist, call 800-789-PENN (7366).

Need an appointment? Request one online 24 hours/day, 7 days/week or call 800-789-PENN (7366) to speak to a referral counselor.

Link:

preimplantation genetic diagnosis - Penn Medicine